EMA: We're firmly convinced of the benefits of the Astrazeneca vaccine

The EMA is investigating reports of blood clots following the Astrazeneca vaccine, but does not change its recommendation.


The European Medicines Agency (EMA) remains "highly convinced" that the benefits of the Astrazeneca vaccine outweigh its risks, according to EMA Executive Director Emer Cooke at a Tuesday press conference.

"We are still firmly convinced that the benefits of the Astrazeneca vaccine in preventing Covid-19 with its associated risk of hospitalization and death outweigh the risk of these side effects," she says.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs